Lupin plans to expand its product portfolio including complex generic drugs and specialty magazines in the global marketplace, exploring new partnership opportunities.

India: Mumbai-based Pharma company Lupin has entered into an agreement with Shenzhen Foncoo Pharmaceutical Co. Ltd. to sell products in the Chinese healthcare market. Lupin’s first partnership in China reinforces the company’s vision to provide affordable and high-quality medicines to patients across the world. The Indian pharma company plans to extend its roots overseas by forming partnerships and catering to global audiences to meet their healthcare needs.

Currently, Lupin has 15 manufacturing units, 7 R&D centers, and 20,000 skilled professionals working around the world. The company commercializes its biotechnology products, APIs, and genetic formulations in over 100 markets, including the United States, South Africa, across Asia-Pacific and Middle East region.

On the newly formed partnership with Foncoo, Lupin President said, “Lupin continues to invest in key growth markets. With China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high-quality generic and complex generic products. We are very excited about our partnership with Foncoo. We will continue exploring additional partnership opportunities in China to leverage our global portfolio, including complex generics and specialty medicines.”

General Manager, Foncoo said, “Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make our perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-value and complex medicines to the Chinese physicians and patients.”

Commenting on the growing number of cross-border partnerships with the healthcare sector, TechSci Research Director, Karan Chechi said, “The B2B collaborations have been vital in positioning India as a global leader in the pharmaceutical sector. The tie-ups are greatly beneficial for industries to expand market reach as well as build local capacities, fundamental to make healthcare more accessible and affordable. In the coming years, greater global associations would help India make a prominent impact on global health security.”

According to TechSci Research report on “India Active Pharmaceutical Ingredients Market By Method of Synthesis (Synthetic v/s Biological), By Source (Contact Manufacturing Organizations v/s In-house Manufacturing), By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type (Generics v/s Innovator), By Region, Competition Forecast & Opportunities, FY2027”, Indian active pharmaceutical ingredients market is projected to grow at a CAGR of 12.24% during the forecast period. The factors largely contributing to the growth are increasing geriatric population and growing prevalence of chronic diseases in the country.

According to another TechSci research report on “India Over the Counter (OTC) Drugs Market By Product (Cough, Cold and Flu, Analgesics, Dermatology Products, Vitamins, Mineral and Supplements (VMS), Other), By Dosage Form (Tablets, Capsules, Powders, Ointments, Liquids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Other), By Company, By Region, Forecast & Opportunities, FY2026”, India OTC drugs market is anticipated to grow at a formidable rate during the forecast period. Greater accessibility and affordability of OTC drugs as well as rising awareness among population pertaining to the application of medicines are expected to drive the growth of Indian over the counter drugs market.